Compare Amphastar Pharmaceuticals Inc (AMPH) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs PAGSEG Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while PAGSEG Inc trades at $9.37 (market cap $2.59B). The key difference: PAGSEG Inc is far larger — about 3.1× Amphastar Pharmaceuticals Inc's market cap, and PAGSEG Inc pays a 11.24% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PAGS | |
|---|---|---|
Market Cap | $826.08M | $2.59B |
Sector | Health | Technology |
52-Week High | $30.81 | $12.00 |
52-Week Low | $16.87 | $7.75 |
Enterprise Value | $1.22B | $10.22B |
Dividend Yield | — | 11.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
PAGS trades at $9.25, up 2.78% with neutral technical indicators showing support at $9 and resistance at $9. The stock presents strong value fundamentals with a P/E of 6.55 and P/B of 0.92, supported by solid profitability including 10.4% net margins and 14.52% ROE. Recent earnings showed mixed results with a Q1 2026 miss but Q4 2025 beat, while the company maintains robust cash flow generation of $7.56B from operations.
The investment case centers on deep valuation discounts and Brazil's rate-cutting cycle potential, though execution risks and competitive pressures remain. Analyst consensus is strongly bullish with 62.5% buy ratings, viewing current levels as attractive for long-term investors given the company's banking and credit expansion trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
